Leerink downgraded Centessa (CNTA) to Market Perform from Outperform with a $40 price target after Eli Lilly (LLY) announced an agreement to acquire the company for $38 per share in cash plus a non-transferable contingent value right worth up to $9 per share.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CNTA:
- Eli Lilly to Acquire Centessa Pharmaceuticals in Cash Deal
- Morning News Wrap-Up 3/31/26: Today’s Biggest Stock Market Stories!
- Alkermes jumps 15% on renewed biotech M&A buzz, says Leerink
- Centessa acquisition ‘may help rouse’ Alkermes shares, says RBC Capital
- Alkermes jumps after Eli Lilly acquires peer Centessa